



Essential Cystitis Framework: Medication-based Management and Detection

**Yash Srivastav^{a+++*}, Firoj Sarwar^a, Aditya Srivastav^b
and Mohd. Imtiyaz Ahmad^a**

^a Azad Institute of Pharmacy & Research, Lucknow, U.P, India.

^b Institute of Pharmacy Bundelkhand University, Kanpur Road Jhansi, Uttar Pradesh, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/sajrm/2024/v18i7371>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/118611>

Review Article

Received: 10/04/2024

Accepted: 14/06/2024

Published: 17/06/2024

ABSTRACT

Bladder inflammation, commonly brought on by a bladder infection, is known as cystitis. This sort of urinary tract infection (UTI) is widespread, especially in women, and is usually not as significant of a problem as it seems. Bacteria in the lower urinary tract are typically the cause of cystic cystitis. The bacteria *Escherichia coli* is typically the cause, accounting for 95% of cases. Bacteria can occasionally enter the bladder through the urethra and cause cystitis, an inflammation of the bladder typically brought on by a bladder infection. It's a prevalent kind of urinary tract infection (UTI), especially in women, and typically only causes minor discomfort rather than alarm. When treating women with simple acute cystitis, trimethoprim-sulfamethoxazole (TMP-SMX), fosfomycin, or nitrofurantoin monohydrate/macrocrystals are the first-choice medications. When other

⁺⁺ Master of Pharmacy in Pharmaceuticals and Assistant Professor;

^{*}Corresponding author: Email: neelashrv76@gmail.com;

suggested medications are not effective, beta-lactam antibiotics may be utilized. 33.54% of people had a UTI, with 66.78% female and 33.22% male. In India, there was a higher frequency in females than in males (2:1). 2019 estimates for the world included 404.61 million cases, 236,790 deaths, and 520,200 DALYs. Specifically, there was a 2.4-fold increase in deaths between 1990 and 2019, and the age-standardized mortality rate (ASMR) went from 2.77/100,000 to 3.13/100,000. In this review study, we discuss the causes, prevalence, available treatments, and current status of cystitis.

Keywords: Cystitis; epidemiology; etiology; pathophysiology; diagnosis; medication.

1. INTRODUCTION

An infection of the lower urinary tract, or more precisely, the bladder, is referred to as cystitis. It falls into one of two general categories: difficult or basic (simple). A lower urinary tract infection (UTI) in otherwise healthy males or non-pregnant women is referred to as "uncomplicated cystitis." Conversely, complex cystitis is linked to risk factors that raise the possibility and severity of infection or the possibility that antibiotic treatment won't work. Urinary bladder irritation, or cystitis, has a variety of causes that are frequently unclear. Our comprehension of cystitis is based on the incomplete but constantly expanding body of information regarding the structure-function links of the urinary bladder and its interactions with other organ systems, particularly the neurological system [1,2,3]. The urinary bladder wall comprises the adventitia/serosa, muscular propria, and mucosa. The urothelium, the epithelium facing the urine, the lamina propria, and the basal lamina, which divides the urothelium from the underlying connective tissue, are all found in the mucosa. The extracellular matrix of lamina propria comprises fibroblasts, myofibroblasts/interstitial cells, immunological cells, and afferent and efferent neurons, among other cell types. Furthermore, smooth muscle bundles (muscularis mucosae), elastic fibres, and blood and lymphatic vessels are found in the lamina propria. The muscular mucosa is ill-defined in the human bladder and occasionally appears missing. Clinically speaking, dysuria, urgency, frequency, and lower abdominal pain

are symptoms of cystitis. While bacterial infections are the most common cause of cystitis, non-infectious diseases like carcinoma in situ, bladder cancer, and bladder stones can also cause the syndrome, as can interstitial cystitis, which can have an unclear etiology. Urologists may typically distinguish cystitis with infectious and noninfectious etiology. Uncomplicated and complicated cystitis are two other classifications for the group of infectious cystitis. An infection in women with a physically and functionally normal urinary bladder is what is known as uncomplicated cystitis. Complicated cystitis, on the other hand, is linked to an aberrant urinary bladder, either physically or functionally, wherein the host becomes compromised and the germs become resistant to antibiotics. Using the right treatment after a rigorous differential diagnosis is necessary to successfully manage cystitis in the majority of cases [3a,3b]. Lower urinary tract infections (UTIs) in otherwise healthy men and non-pregnant women are referred to as "uncomplicated cystitis." A urinary bladder bacterial infection is usually the cause of acute cystitis. Conversely, risk variables linked to complicated cystitis raise the possibility of antibiotic therapy failure or the infection's severity. A urinary bladder bacterial infection is usually the cause of acute cystitis. Because of the closeness of the rectum to the urethral meatus and the relatively short urethral length of females, women are especially vulnerable. In addition to reviewing the diagnosis and treatment of cystitis, this activity outlines the function of the interprofessional team in the patient's care [3c,4].




Fig. 1. Infection by cystitis

2. EPIDEMIOLOGY AND HISTORICAL PERSPECTIVES

The incidence of complex UTIs varies widely depending on the underlying disease. Women without diabetes have a 6% estimated prevalence of asymptomatic bacteriuria, while women with diabetes have a 26% estimated prevalence. Acute cystitis and pyelonephritis are two more conditions that patients with diabetes are more likely to experience. According to retrospective cohort studies, the incidence of urinary tract infections (UTIs) ranges from 47% to 75% in patients who have had kidney transplantation. By the age of 24 and 32, almost one-third and half, respectively, of women will have experienced a UTI. According to self-reported annual incidence, the incidence of UTI in women is 12%. The annual incidence of UTIs in sexually active women is estimated by a university cohort research to be between 0.5 and 0.7 UTIs per person-year. A strong family history of UTI in a first-degree female relative, postmenopausal status, previous UTI, new sex partner within the last year, sexual activity, and spermicide usage are all risk factors for simple cystitis. Approximately 18 to 28 bouts of acute cystitis are thought to occur for every episode of pyelonephritis, making acute cystitis far more prevalent than pyelonephritis. During the first year following transplantation, the danger is greatest. 2.3% of expectant mothers experience a symptomatic UTI. Nephrolithiasis, immunocompromised status, foreign bodies such as catheters, urinary tract instrumentation, renal insufficiency, anatomical or functional abnormalities of the urinary tract, urinary strictures, and obstructive uropathy are additional risk factors for developing a complicated UTI. In men, uncomplicated cystitis is rather uncommon. Less than 10 cases are thought to occur annually for every 10,000 men under 65. Men can experience the same symptoms of a basic UTI as women do: suprapubic pain, urgency, frequency, and dysuria. Prostatitis is suggested by recurrent symptoms, reinfections following treatment, fever, and pelvic or perineal pain. Any indicators of a systemic illness, such as a fever, chills, or flank discomfort, point to a complex urinary tract infection [5–8]. Urinary symptoms associated with acute cystitis frequently include dysuria, frequency, urgency, soreness, or tenderness in the suprapubic area, and on rare occasions, hematuria. The combination of dysuria and frequency of urination in the absence of vaginal discharge or irritation is highly predictive of simple cystitis (90% correlation),

according to a comprehensive analysis that looked at the history and examination results of women with uncomplicated UTI. In the extremely young and the very old, symptoms could be mild or unusual. Cloudiness in the urine or a "foul odour" alone, without other symptoms, usually does not support a cystitis diagnosis. Patients with mild cystitis will frequently present differently from those with complex acute cystitis. Atypical symptoms may be present in certain patient populations with complex cystitis. Patients with spinal cord injuries, for instance, may exhibit increased stiffness or autonomic dysfunction, whereas individuals with multiple sclerosis sometimes exhibit abrupt neurologic deterioration. If systemic symptoms like fever, chills, or sepsis are absent, cystitis can be distinguished from pyelonephritis. Symptoms including nausea, vomiting, tenderness around the costovertebral angle, and flank pain point to an upper urinary tract infection or pyelonephritis. Many general symptoms, including fevers, chills, changes in mental or functional status, and falls, are linked to a presumptive diagnosis of UTI in weak and disabled individuals. According to recent data, the only urine symptoms that were consistently linked to verified UTIs were colour changes, odour, gross hematuria, and acute dysuria. Only changes in the colour and odor of the urine may indicate bacteriuria, but there is little data to support the need for antibiotic treatment until or unless further symptoms, such as fever, appear. Hydration (for potential dehydration), monitoring, and an examination for further causes are advised treatments for mental status changes. Studies are inconsistent, therefore mental status changes in these patients may or may not indicate a UTI [9–12].

3. ETIOLOGY

A urinary bladder bacterial infection is usually the cause of acute cystitis. The rectum's close closeness to the urethral meatus and females' comparatively short urethral length makes them more vulnerable. Klebsiella is the most prevalent etiologic agent for women's uncomplicated UTIs, accounting for about 75% to 95% of cases. *Escherichia coli* is the most common cause of UTIs in women. *Proteus mirabilis* and other members of the Enterobacteriaceae family, as well as other bacteria like *Staphylococcus saprophyticus* and *enterococcus*, are examples of prevalent etiologic pathogens. When isolated from the urine culture of an otherwise healthy individual, other bacterial species typically indicate contamination rather than the unusual

cause of urinary tract infections. These include microorganisms other than *S. saprophyticus* that are coagulase-negative *staphylococci*, such as *Lactobacillus* and Group B streptococci. The most frequent cause of complicated cystitis is likewise *Escherichia coli*; however, a far wider range of microorganisms, including *Enterobacter*, *Citrobacter*, *Serratia*, *Pseudomonas*, *enterococci*, *staphylococci*, and even fungus, can also result in a complicated UTI. Antimicrobial resistance is also substantially more common in complex infections. Notable resistant organisms include bacteria that produce the extended-spectrum beta-lactamase (ESBL), as well as organisms that are resistant to carbapenem and fluoroquinolones, especially *E. coli* [13–17].

4. PATHOPHYSIOLOGY

The most common cause of cystitis is the colonization of the periurethral mucosa by bacteria from the vaginal or faecal flora, which then spreads to the bladder. Uropathogens may possess microbial virulence factors that enable them to penetrate urinary tract tissues and evade host defences. Because of the longer physical urethra, the drier periurethral environment, and the prostatic fluid's antibacterial defences, urinary tract infections (UTIs) are far less common in men. In the past, male UTIs were all thought to be difficult. But occasionally, especially in men between the ages of 15 and 50, uncomplicated UTIs can happen, especially to those who engage in sexual activity, are not circumcised, or have anal sex, provided they don't have any risk factors for complicated UTIs like urologic abnormalities, bladder outlet obstruction, urolithiasis, or recent urinary tract instrumentation. Complicated UTI pathogenesis is primarily determined by the underlying host variables. Diabetes patients may be more susceptible to urinary tract infections (UTIs) due to immune system impairment and autonomic neuropathy-related voiding dysfunction. Reduced renal blood flow and the buildup of uremic toxins can both weaken host defences and hinder the removal of microorganisms from the body. Kidney stones have the potential to become an obstruction and an infection source. When a person is placed on a urinary catheter, bacteria may continue to live in retained urine pools in the bladder and develop internal and exterior biofilms on the catheter. *Escherichia coli* is the most commonly identified bacteria responsible for cystitis, accounting for 75% to 95% of cases. *Proteus mirabilis* and *Klebsiella pneumoniae* are two other pathogens that can cause cystitis.

(*Klebsiella*, after *E. coli*, is the most prevalent cause of UTIs.) Patients may arrive with *staphylococci*, *enterococci*, and *pseudomonas*, including *S. saprophyticus* if they have recently been hospitalized or have received therapy for a UTI. Numerous additional organisms, including coagulase-negative *staphylococci*, lactobacilli, and Group B streptococci, are typically regarded as pollutants unless they are present in extremely high concentrations in an environment where an infection is feasible [18–20].

5. DIAGNOSIS

Acute cystitis is typically diagnosed clinically in patients with symptoms and indications typical of a lower urinary tract infection (UTI) together with pyuria and/or nitrites in the laboratory. Physical examination results may be more significant for individuals with pyelonephritis or vaginitis, although they are frequently not required for the diagnosis of cystitis. Frequently, in young, non-pregnant women exhibiting classic symptoms of cystitis, particularly when vaginal discharge or irritation is absent, clinical suspicion may be adequate for diagnosis and therapy initiation without test confirmation. It is, however, strongly advised to get a urine culture and urinalysis before beginning antibiotic treatment. There won't be enough clinical data to properly manage treatment modifications if the patient doesn't get better after taking the first antibiotic. When required, urinalysis is the most crucial laboratory test for the diagnosis of urinary tract infection (UTI). A clean catch sample is typically adequate, but a prompt urethral catheterization should be taken into consideration if an uncontaminated specimen with few epithelial cells cannot be acquired in any other way, as in the case of some morbidly obese women. Women who have never had a UTI before have a 1% chance of developing one after a single urethral catheterization. Urine's outside look is infamously inaccurate in determining the presence of a urinary tract infection. When protein or calcium phosphate particles generate "cloudiness" in urine, it can be sterile, but clear urine can be seriously contaminated. A straightforward test involves putting a few drops of glacial acetic acid into a test tube containing the murky urine sample. If doing so makes the "cloudiness" go away, the urine probably contains a lot of calcium phosphate particles. Pyuria is nearly always present when there are at least 10 white blood cells (WBCs)/HPF or leukocytes in unspun midstream urine samples. A different diagnosis may be suggested if pyuria

is absent. A UTI can also be diagnosed with urinary dipsticks. Leukocyte esterase, an enzyme generated by leukocytes, and nitrites, which signify the presence of Enterobacteriaceae, are detected. A positive nitrite test suggests or is strongly indicative of bacteriuria since nitrates can only be converted to nitrites in the presence of bacteria. In general, only Enterococcus, Pseudomonas, and Acinetobacter are unable to change nitrates into nitrites. Patients with typical symptoms of acute cystitis can benefit from a confirmatory test for leukocyte esterase or nitrites with a positive dipstick test result. However, a negative dipstick test does not always rule out a UTI diagnosis [21–26]. If nitrites are positive, it makes sense to treat individuals with UTI symptoms with antibiotics; however, if leukocyte esterase is negative, another diagnosis should be taken into account. Positivity for both leukocyte esterase and nitrites has a high positive predictive value (85%) and a high negative predictive value (92%). Anti-microbial susceptibility profiles and etiologic pathogen identification can both benefit from a urine culture. A rise of more than or equal to 1,000 CFU is deemed significant in men and samples taken after straight bladder catheterization. A value of more than or equal to 100,000 CFU (colony forming units)/mL suggests clinically relevant bacteriuria. A urinary tract infection is not ruled out if the CFU/mL is less than 100,000. Urine cultures, on the other hand, are rarely performed in cases of acute, simple cystitis and are frequently deemed unnecessary, although they can be highly beneficial for patients who have prolonged symptoms and are thought to be receiving ineffective treatment—especially in light of the rising prevalence of antibiotic resistance. Before starting antibiotic therapy, all men with symptoms of acute cystitis and women with risk factors for complex UTIs need to have urine cultures and urinalyses done. They are also recommended for individuals who have unusual symptoms, those who don't improve with therapy, and those whose symptoms return in two to four weeks. Fertile women should have a pregnancy test performed on them. Men who experience repeated bouts of cystitis ought to have prostatitis evaluated. The urologic evaluation may not be necessary for young men who are sexually active and have experienced a single episode of cystitis. Urologic assessment and workup should be initiated if risk indicators for a complex UTI are present. If adequate antibiotic treatment is not effective within 48 to 72 hours for patients with complex cystitis, additional examination using upper urinary tract

radiography imaging may be necessary. Ultrasonography or computed tomography (CT) may be used for this. When it comes to identifying aberrant processes such as urinary blockage, stones, diverticula, or abscess formation that could impede the effectiveness of treatment, CT imaging is typically the preferred test due to its higher sensitivity. In patients who should minimize radiation exposure or who should otherwise avoid CT imaging, renal ultrasound, particularly when paired with a KUB (short for kidneys, ureters, and bladder; i.e., a flat plate of the abdomen), may be sufficient [7,18,27,28].

6. MEDICATION-BASED CYSTITIS MANAGEMENT

Men's cystitis is comparatively rare and has not been extensively researched. The course of treatment for a healthy guy with no symptoms or risk factors for a severe urinary tract infection should be the same as that prescribed for women with similar conditions. Fluoroquinolones have been suggested for initial use as empiric therapy for males with severe symptoms, morphological or urologic abnormalities, or suspicion of prostate involvement, awaiting results from culture and susceptibility tests as well as local patterns of quinolone resistance. When feasible, quinolones are the first choice because of their high tissue penetration levels and wide range of activity. To reduce quinolone resistance, doxycycline, SMX-TMP, and cephalosporins may also be used initially. Every man who has a UTI that has been properly identified is usually regarded as having a difficult illness and is susceptible to chronic prostatitis, which may not show symptoms for weeks or even months following the initial infection. Because of this, some advise treating all men with UTIs for at least four to six weeks with prostate-penetrating antibiotics (doxycycline, SMX-TMP, quinolones) to allow for the development of appropriate antibiotic concentrations inside the prostate and lower the risk of developing chronic prostatitis later on. Patients who experience a return of symptoms within a few weeks or who do not react to a suitable antibiotic regimen after 48 to 72 hours may need to be evaluated further, with a focus on resistant organisms or other possible causes. Patients should be treated with a different empirical antimicrobial drug, and the regimen should then be tailored based on the results of susceptibility testing and urine culture. Vaginitis and urethritis are potential diagnoses for female

patients presenting with dysuria. Typically, vaginal discharge, dyspareunia, and pruritus are linked to vaginal infections. Yeast infection, trichomoniasis, and bacterial vaginosis are some of its causes. Patients who experience chronic symptoms of bladder discomfort without any indication of an infectious cause may be diagnosed with painful bladder syndrome. But this is an exclusionary diagnosis. Men with lower UTI symptoms should have prostatitis ruled out, particularly if it is accompanied by fever, malaise, perineal pain, or symptoms of obstructed urination. Suspicion of chronic bacterial prostatitis should be increased in male patients who experience recurrent UTIs [7,15].

For 5-7 days, take 100 mg twice a day of nitrofurantoin. For three days, take double-strength sulfamethoxazole-trimethoprim (SMX-TMP) twice a day (if local antibiotic resistance is less than 20%). 3 grams of fosfomycin taken orally in one dose. For five to seven days, use 400 mg twice daily of pivmecillinam (not licensed in the US). In most cases, nitrofurantoin is the antibiotic of choice for cases of uncomplicated cystitis. It has a high clinical cure rate of 79% to 92%, doesn't encourage resistance or yeast overgrowth, and is safe to use even in elderly individuals as long as their glomerular filtration rate is greater than 60 ml/min. Since it doesn't penetrate tissue well, people with fevers, pyelonephritis, or other signs of a systemic infection shouldn't use it. *Proteus*, *Morganella*, and *Providencia* are among the *Proteeae* group of organisms that are less effective against nitrofurantoin because they generate urease, which elevates the pH of the urine. It has been demonstrated that when the urine pH is 8 or higher, nitrofurantoin is less efficient in treating UTIs. Instead of being a bacteriocidal medication, nitrofurantoin is a bacteriostatic one. As a result, it shouldn't be administered for fewer than five days. When local antibiotic resistance is less than 20%, sulfamethoxazole-trimethoprim (SMX-TMP) is advised. It penetrates tissue well, even into the prostate. The reported range for the overall clinical cure rate is 79% to 100%. Those with sulfa allergies can benefit from trimethoprim taken alone with comparable effectiveness. Regrettably, resistance to SMX-TMP often emerges quickly. The overall clinical cure rate of fosfomycin and nitrofurantoin is comparable. It is not commonly utilized in the US since urine cultures frequently do not include it. It is not advised for early routine usage because it still has activity against several drug-resistant pathogens, such as *Enterococcus* and *E. Coli*.

Both Gram-positive and Gram-negative germs, including strains resistant to vancomycin, can be treated with it. When used against *Pseudomonas* and *Klebsiella*, it is less effective. Additionally, because of insufficient renal tissue levels, it should not be used in cases of confirmed or suspected pyelonephritis. It's a bacteriocidal medication that's not used much. Because pivmecillinam has relatively little documented bacterial resistance, it is utilized in nations other than the US, especially in the Nordic region. This penicillin is limited to usage in the urinary tract and has an expanded spectrum. It does not considerably increase antibiotic resistance, similar to nitrofurantoin, but because of its low tissue penetration, it is also ineffective in treating systemic infections or pyelonephritis. Antibiotics are usually taken for 10 to 14 days to treat complicated illnesses. Appropriate measures should be implemented since people with diabetes are more likely to develop yeast infections during and right after receiving antibiotic treatment. A patient's history of allergies, side effects, tolerability, local patterns of bacterial resistance, possible drug interactions, cost and insurance coverage, renal function, compliance history, and recent use of a particular antimicrobial agent within the previous three months should all be taken into consideration when choosing an antibiotic. Patients with a glomerular filtration rate (GFR) of less than 60 mL/min or those with creatinine clearance should not take nitrofurantoin. On the other hand, patients allergic to sulfa or in areas where regional resistance exceeds 20% should not take SMX-TMP. Risk factors for this kind of resistance include travel, particularly overseas travel, usage of SMX-TMP within the last six months, and recent past healthcare contact. Nitrofurantoin use is also prohibited if pyelonephritis or a complex UTI is suspected. If a patient is at danger of having multiple drug-resistant (MDR) organisms, their antimicrobial regimens must be guided by urine culture and sensitivity tests. A prior MDR isolate (resistance to three or more antibiotic classes), a recent hospital visit, recent travel to a place where MDR organisms are highly prevalent, or usage of broad-spectrum antimicrobial drugs within the last three months are risk factors. Nitrofurantoin, SMX-TMP, fosfomycin, and pivmecillinam (if available) make up the proper empirical regimen. Delaying treatment until culture and susceptibility findings are available is an alternate strategy, particularly if using any of the aforementioned first-line medicines is prohibited for whatever reason. Patients with severe dysuria may get

analgesics for symptomatic relief. Although phenazopyridine is a urine analgesic, it is not therapeutic and will not alter the course of an infection clinically. It is used in the short term to alleviate urinary dysuria or discomfort [29,30,31-40,41,42–46,47–53].

7. DISCUSSION AND CONCLUSION

Our review articles begin with an overview of cystitis, including its various origins, epidemiology, and alternate treatments. Our findings demonstrate that medications do work to treat. Further randomised controlled studies are needed for the treatment of cystitis. In the future, we intend to conduct a preliminary investigation on cystitis. With the support of our colleagues, future counselling-based research in our country or state will assess the physical and emotional health of patients and produce more accurate data on cystitis and its treatment.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

ACKNOWLEDGEMENT

The authors would like to thank, Azad Institute of Pharmacy & Research (AIPR), Lucknow, U.P, India, Lucknow, Uttar Pradesh, India for extending their facilities.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Lương, Khanh vinh quốc, Lan Thi Hoàng Nguyễn. The roles of β -adrenergic receptor blockers in interstitial cystitis. *Journal of Advances in Medicine and Medical Research*. 2013;3(4):12851301. Available:https://doi.org/10.9734/BJMMR/2013/2938.
2. Bijou MR, Josephine A, Lilly SM. Cystitis glandularis with intestinal metaplasia. *Journal of Pharmaceutical Research International*. 2022;34(5A):37–42. DOI: 10.9734/jpri/2022/v34i5A35407.
3. Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: A systematic review. *The Journal of urology*. 2007, Feb 1;177(2):450-6.
- 3a. Paner GP, Ro JY, Wojcik EM, Venkataraman G, Datta MW, Amin MB. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. *Yatayat*. 2007, You;12y(235):245. Available:http://digilib.unila.ac.id/4949/15/BAB II.pdf
- 3b. Lee G, Romih R, Zupančič D. Cystitis: From urothelial cell biology to clinical applications. *Biomed Res Int*. 2014; 2014.
- 3c. Duane S, Vellinga A, Murphy AW, Cormican M, Smyth A, Healy P, et al. COSUTI: A protocol for the development of a core outcome set (COS) for interventions for the treatment of uncomplicated urinary tract infection (UTI) in adults. *Trials*. 2019, Feb;20(1):106.
4. Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. 2019, Sep;33(9):e13507.
5. Suárez Fernández ML, Ridao Cano N, Álvarez Santamarta L, Gago Fraile M, Blake O, Díaz Corte C. A current review of the etiology, clinical features, and diagnosis of urinary tract infection in renal transplant patients. *Diagnostics (Basel, Switzerland)*. 2021, Aug;11(8).
6. Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, et al. The 2017 update of the german clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: Therapy and Prevention. *Urol Int*. 2018;100(3):271–8.
7. Sabih A, Leslie SW. *Complicated Urinary Tract Infections*. In Treasure Island (FL); 2024.
8. Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. *J Urol*. 1993, May;149(5):1046–8.
9. Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: A cross-sectional study

- of 32 nursing homes. *BMC Fam Pract.* 2011, May;12:36.
10. Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: A cohort study. *J Am Geriatr Soc.* 2009, Jun;57(6):963–70.
 11. Nace DA, Drinka PJ, Crnich CJ. Clinical uncertainties in the approach to long term care residents with possible urinary tract infection. *J Am Med Dir Assoc.* 2014, Feb;15(2):133–9.
 12. Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. *J Urol.* 2019, Aug;202(2):282–9.
 13. Byron JK. Urinary tract infection. *Vet Clin North Am Small Anim Pract.* 2019, Mar;49(2):211–21.
 14. Karamali M, Shafabakhsh R, Ghanbari Z, Eftekhari T, Asemi Z. Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression. *J Cell Physiol.* 2019, Aug;234(8):12301–8.
 15. Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, et al. Antimicrobial susceptibility trends observed in urinary pathogens obtained From New York State. *Open forum Infect Dis.* 2018, Nov;5(11):ofy297.
 16. Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ. Fluoroquinolone-resistant and extended-spectrum β -lactamase-producing *Escherichia coli* infections in patients with pyelonephritis, United States(1). *Emerg Infect Dis.* 2016, Sep;22(9):1594–603.
 17. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, et al. *Escherichia coli* sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. *Clin Infect Dis an Off Publ Infect Dis Soc Am.* 2013, Nov;57(9):1256–65.
 18. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. *N Engl J Med.* 2013, Nov;369(20):1883–91.
 19. Pinto H, Simões M, Borges A. Prevalence and impact of biofilms on bloodstream and urinary tract infections: A systematic review and meta-analysis. *Antibiot (Basel, Switzerland).* 2021, Jul;10(7).
 20. Tyagi P, Moon CH, Janicki J, Kaufman J, Chancellor M, Yoshimura N, et al. Recent advances in imaging and understanding interstitial cystitis. *F1000Research.* 2018;7.
 21. May M, Schostak M, Lebentrau S. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: A call for its implementation in clinical routine. *International urogynecology journal.* England. 2019;30:335–6.
 22. Swamy S, Kupelian AS, Khasriya R, Dharmasena D, Toteva H, Dehpour T, et al. Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria and negative urinalysis. *Int Urogynecol J.* 2019, Mar;30(3):409–14.
 23. Bono MJ, Leslie SW, Reygaert WC, Doerr C. Uncomplicated Urinary Tract Infections (Nursing). In *Treasure Island (FL)*; 2024.
 24. Phamnguyen TJ, Murphy G, Hashem F. Single centre observational study on antibiotic prescribing adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infection. *Infect Dis Heal.* 2019, May;24(2):75–81.
 25. Kulchavenya E V, Neymark AI, Borisenko DV, Kapsargin FP. [Acute uncomplicated cystitis: do we follow the guidelines?]. *Urologiia.* 2018, Dec;(6):66–9.
 26. Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV. Duration of antibiotic treatment for common infections in English primary care: Cross sectional analysis and comparison with guidelines. *BMJ.* 2019, Feb;364:l440.
 27. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. *Clin Infect Dis an Off Publ Infect Dis Soc Am.* 2004, Apr;38(8):1150–8.
 28. Bellazreg F, Abid M, Lasfar N Ben, Hattab Z, Hachfi W, Letaief A. Diagnostic value of dipstick test in adult symptomatic urinary tract infections: Results of a cross-sectional Tunisian study. Vol. 33, *The Pan African Medical Journal.* Uganda; 2019; 131.
 29. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. *Clin Microbiol Rev.* 2016 Apr;29(2):321–47.
 30. De Nunzio C, Bartoletti R, Tubaro A, Simonato A, Ficarra V. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. *Antibiot (Basel, Switzerland).* 2021, Apr;10(4).

31. Nace DA, Perera SK, Hanlon JT, Saracco S, Anderson G, Schweon SJ, et al. The Improving Outcomes of UTI Management in Long-Term Care Project (IOU) Consensus Guidelines for the Diagnosis of Uncomplicated Cystitis in Nursing Home Residents. *J Am Med Dir Assoc.* 2018, Sep;19(9):765-769.e3.
32. Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borriild N, Bru JP, et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. *Scand J Infect Dis.* 2002;34(7):487–92.
33. Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. *Int J Antimicrob Agents.* 2003, Oct;22(Suppl 2):73–8.
34. Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, et al. Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study. *Open forum Infect Dis.* 2022, Jan;9(1):ofab620.
35. Hatlen TJ, Flor R, Nguyen MH, Lee GH, Miller LG. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: A 1year review of outcomes and prescribing habits in a large municipal healthcare system. *J Antimicrob Chemother.* 2020, Jul;75(7):1993–7.
36. Schulz GS, Schütz F, Spielmann FVJ, da Ros LU, de Almeida JS, Ramos JGL. Single-dose antibiotic therapy for urinary infections during pregnancy: A systematic review and meta-analysis of randomized clinical trials. *Int J Gynaecol Obstet Off organ Int Fed Gynaecol Obstet.* 2022, Oct;159(1):56–64.
37. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. *Clin Ther.* 1999, Nov;21(11):1864–72.
38. Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. *J Infect Dis.* 1988, Jun;157(6):1239–42.
39. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. *Infectious Diseases Society of America (IDSA). Clin Infect Dis an Off Publ Infect Dis Soc Am.* 1999, Oct;29(4):745–58.
40. Kavatha D, Giamarellou H, Alexiou Z, Vlachogiannis N, Pentea S, Gozadinos T, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. *Antimicrob Agents Chemother.* 2003, Mar;47(3):897–900.
41. Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: A systematic review and meta-analysis. *Am J Obstet Gynecol.* 2020, Aug;223(2):265.e1-265.e13.
42. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. *J Antimicrob Chemother.* 1999, Mar;43 (Suppl A):67–75.
43. Sheele JM, Libertin CR, Fink I, Jensen T, Dasalla N, Lyon TD. Alkaline urine in the emergency department predicts nitrofurantoin resistance. *J Emerg Med.* 2022, Mar;62(3):368–77.
44. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: A systematic review and meta-analysis of controlled trials. *J Antimicrob Chemother.* 2015, Sep; 70(9):2456–64.
45. McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. *Mayo Clin Proc.* 2011, Jun;86(6):480–8.
46. Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, et al. Appropriate use of short-course antibiotics in common infections: Best practice advice From the American College of Physicians. *Ann Intern Med.* 2021, Jun;174(6):822–7.
47. Kyriakides R, Jones P, Somani BK. Role of D-mannose in the prevention of recurrent urinary tract infections: Evidence from a systematic review of the literature. *Eur Urol Focus.* 2021, Sep;7(5):1166–9.
48. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women:

- A randomized clinical trial. World J Urol. 2014, Feb;32(1):79–84.
49. Kevorkian CG, Merritt JL, Ilstrup DM. Methenamine mandelate with acidification: An effective urinary antiseptic in patients with neurogenic bladder. Mayo Clin Proc. 1984, Aug;59(8):523–9.
50. Lo TS, Hammer KDP, Zegarra M, Cho WCS. Methenamine: A forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Rev Anti Infect Ther. 2014, May;12(5):549–54.
51. Ziadeh T, Chebel R, Labaki C, Saliba G, Helou E El. Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic review. Urologia. 2022, May;89(2):261–7.
52. Lala V, Leslie SW, Minter DA. Acute Cystitis. In Treasure Island (FL); 2024.
53. Cox L, He C, Bevins J, Clemens JQ, Stoffel JT, Cameron AP. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. Can Urol Assoc J = J l'Association des Urol du Canada. 2017, Sep;11(9):E350–4.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/118611>